DR-18 based CAR-T / Simcha Therap, J&J - LARVOL DELTA

Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications (Businesswire) - "Simcha Therapeutic...today announced that it has entered into a license and option agreement with Janssen Biotech, Inc. ('Janssen'), a Johnson & Johnson company, where Janssen will work to armor select CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18). The agreement was facilitated by Johnson & Johnson Innovation....Under the terms of the agreement, Janssen will develop, manufacture, and commercialize DR-18 armored cell therapies for a set number of programs. In exchange, Simcha will receive an undisclosed upfront fee, potential option exercise fees and development and commercialization milestone payments."

Licensing / partnership • Oncology